Tenacia Biotechnology Deal History & Licensing Activity
Tenacia Biotechnology is a life sciences. Over the past three years, Tenacia Biotechnology has been involved in 1 licensing and acquisition transaction, with a primary focus on Allosteric Inhibitor (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Allosteric Inhibitor
Focus Area
Neurology
Tenacia Biotechnology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Tenacia Biotechnology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| RAP-219 | Rapport Therapeutics | Allosteric Inhibitor | Phase 2 | license | Mar 2026 |
Tenacia Biotechnology Pipeline Focus
Therapeutic areas and modalities where Tenacia Biotechnology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Tenacia Biotechnology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Allosteric Inhibitor Benchmarks
Upfront, milestone, and royalty benchmarks for allosteric inhibitor deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Tenacia Biotechnology Licensing & Deal Activity
Tenacia Biotechnology is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Tenacia Biotechnology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Tenacia Biotechnology include Neurology (2 deals and trials). In terms of modality, Tenacia Biotechnology has shown particular interest in allosteric inhibitor.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Tenacia Biotechnology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Tenacia Biotechnology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.